LDS/Medical Tests/Class of Anticonvulsants

Class of Anticonvulsants

The class of drugs known as anticonvulsants are designed to help the physician in treating patients with seizures. The most common type of seizure the physician encounters in clinical medicine are epileptic seizures. Basically a seizure is an abnormal, excessive firing of neurons in the gray matter of the brain. A seizure may cause violent, involuntary muscular contractions known as convulsions. Nonconvulsive seizures can also occur in patients and these symptoms are staring and very subtle movements. Epilepsy is a disease of the brain in which an individual experiences recurrent seizures. Seizures can be due to a secondary process of another disease state. Children may develop seizures as a result of a fever, known as febrile seizures. Alcoholics that are going through ethanol withdrawal may also develop seizures, as well as those that develop a seizure due to brain trauma or injury. The treatment of seizures is based upon the type of seizure encountered. Seizures are divided into partial, generalized, and unclassified. Partial seizures are focal and localized within one hemisphere of the brain. Generalized seizures involve both hemispheres of the brain of which there are seven types: tonic-clonic or grand mal, tonic, clonic, myoclonic, atonic, absence, and atypical absence. Unclassified seizures are those that do not fit into any of the above categories.

Various drugs have been developed to aid the physician in treatment of these types of seizures. Pharmacokinetics and therapeutic drug monitoring have evolved to aid the physician in dosing the prescribed medication used to treat these types of seizures.

The term Therapeutic Drug Monitoring is defined as the measurement of therapeutic drugs in biological specimens by aiding in optimizing the therapeutic effect and limiting the toxic effects of drugs. Therapeutic drug monitoring came into being from the clinicians need to be able to adjust dosing regimens according to the patient’s response to the drugs. By measuring the quantity of drug present in the patient’s blood after a dose, the pharmacological effect can be interpreted and the dosing regimen can be adjusted to avoid a toxic outcome. Patient compliance can also be determined by quantifying the drug level after a dose. The clinician must be certain that the patient is actually taking the prescribed medication in a manner that is most effective to achieve the desired outcome. However, as with most medications, if taken contrary to the way they are prescribed or in the dose that they are prescribed, can result in serious side effects that can be life threatening in some cases.

As with most therapeutic drugs, many of this class of drugs are extensively metabolized in the liver but absorbed mainly in the small intestine. Most of this class of medications are administered orally. Anticonvulsants can elicit the following effects: amnesia, hostility, irritability, and vivid or disturbing dreams. Overdose effects include shallow respiration, clammy skin, dilated pupils, weak and rapid pulse, coma, and possible death.

  • Therapeutic monitoring
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from an immunoassay type test indicates only the presence of anticonvulsants and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.

Screening: Negative

Therapeutic levels - see individual drug listings 

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.           

Cut-Off Ranges

Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy). This particular method of analysis is used to not only detect the parent drug class of anticonvulsants, but also the major metabolites. Anticonvulsants can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. In general, anticonvulsants are not extensively bound to protein and usually appear in the urine as the glucuronide conjugate. When analyzing urine specimens a hydrolysis step is required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis.

Urine:

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability (typically):

  • Refrigeration: 7 days
  • Frozen: 14 days

Serum:

Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Plasma specimens are acceptable if drawn in a heparin (green top) tube. Specimens should be spun and the serum or plasma separated and refrigerated.

Stability (typically):

  • Refrigeration: 7-14 days
  • Frozen: 14 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* COMT and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Chromatogr. 1985;340:139-72. [PMID: 3894399]
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Lettleton, MA: PSG Publisging Co.; 1987
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Seal Beach, CA: Biomedical Publications; 2011.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Levine B (ed). Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press. Chapter 22, Anticonvulants and Antiarrhythmics, pp. 391-402; 2013.